Analyst Ratings For Clinigen Group PLC (LON:CLIN)
Today, Peel Hunt raised its price target on Clinigen Group PLC (LON:CLIN) to GBX 1,015 per share.
There are 4 buy ratings on the stock.
The current consensus rating on Clinigen Group PLC (LON:CLIN) is Buy (Score: 3.00) with a consensus target price of GBX 935.75 per share, a potential .
Some recent analyst ratings include
- 1/25/2017-Numis Securities Ltd Reiterated Rating of Buy.
About Clinigen Group PLC (LON:CLIN)
Clinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Company’s principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through five segments: Clinigen Clinical Trial Services (CTS), which sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies; Idis Managed Access (MA), which is engaged in the consultancy, development, management and implementation of managed access programs for biotechnology and pharmaceutical companies; Idis Global Access (GA), which offers ethical access to post approval and short-supply medicines; Clinigen Specialty Pharmaceuticals (SP), which manufactures and distributes its own and in-licensed specialist, hospital-only medicines around the world, and Link Healthcare, which distributes pharmaceutical products in South Africa, and the Asia and Pacific region.
Recent Trading Activity for Clinigen Group PLC (LON:CLIN)
Shares of Clinigen Group PLC closed the previous trading session at 832.00 down -8.00 -0.95% with 102,828 shares trading hands.